NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
59651-0343-28 | 59651-0343 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
59651-0345-07 | 59651-0345 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
69097-0382-73 | 69097-0382 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
60505-4532-02 | 60505-4532 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 9, 2023 | In Use | |
59651-0343-07 | 59651-0343 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
60219-1717-01 | 60219-1717 | Lenalidomide | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
83718-0000-01 | 83718-0000 | Toripalimab-tpzi | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct 27, 2023 | In Use | |
00069-0315-01 | 00069-0315 | Bevacizumab-bvzr | Zirabev | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 13, 2020 | In Use | |
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
72189-0084-24 | 72189-0084 | IMIQUIMOD | IMIQUIMOD | 12.5 mg/.25g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Mar 23, 2020 | In Use | |
65483-0116-07 | 65483-0116 | Aldesleukin | Proleukin | 1.1 mg/mL | Immunotherapy | Cytokine | Interleukin-2 | Intravenous | May 5, 1992 | In Use | |
55513-0141-21 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
59572-0405-28 | 59572-0405 | Lenalidomide | Revlimid | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2009 | In Use | |
00069-0342-01 | 00069-0342 | Bevacizumab-bvzr | Zirabev | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 13, 2020 | In Use | |
60505-4534-01 | 60505-4534 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | Mar 8, 2023 | In Use |
69448-0016-11 | 69448-0016 | Trastuzumab-strf | HERCESSI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use | |
59651-0344-07 | 59651-0344 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
00004-0365-09 | 00004-0365 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 1, 2011 | In Use | |
70710-1030-01 | 70710-1030 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
00378-1942-01 | 00378-1942 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
70771-1677-07 | 70771-1677 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
65219-0668-01 | 65219-0668 | Denosumab | CONEXXENCE | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
55513-0956-01 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
55135-0132-01 | 55135-0132 | SACITUZUMAB GOVITECAN | TRODELVY | 180.0 mg/1 | Immunotherapy | Drug Antibody Conjugate | Trop-2 | Intravenous | Apr 23, 2020 | In Use |
Found 11765 results — Export these results